Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für neurologische Forschung     Collection: Funktionelle Krebsgenomforschung     Display Documents



  history
ID: 610606.0, MPI für neurologische Forschung / Funktionelle Krebsgenomforschung
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET
Authors:Scheffler, Matthias; Kobe, Carsten; Zander, Thomas; Nogova, Lucia; Kahraman, Deniz; Thomas, Roman K.; Neumaier, Bernd; Dietlein, Markus; Wolf, Jürgen
Language:English
Date of Publication (YYYY-MM-DD):2012
Title of Journal:Lung Cancer
Volume:77
Issue / Number:3
Start Page:617
End Page:620
Copyright:© 2012 Elsevier Ireland Ltd. All rights reserved.
Review Status:not specified
Audience:Experts Only
External Publication Status:published
Document Type:Article
Communicated by:Grasse
Affiliations:Arbeitsgruppe Prof. Brüning/Funktionelle Krebsgenomforschung
External Affiliations:a Department I for Internal Medicine, University Hospital of Cologne, Germany
b Center for Integrated Oncology Köln Bonn, Germany
c Clinic for Nuclear Medicine, University Hospital of Cologne, Germany
Identifiers:ISSN:01695002
DOI:10.1016/j.lungcan.2012.05.110
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.